Autoimmunity and atopic dermatitis

Mittermann, Irene; Aichberger, Karl J.; Bünder, Robert; Mothes, Nadine; Renz, Harald; Valenta, Rudolf

doi:10.1097/00130832-200410000-00007

Cited by 76 publications

(61 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent reports showed the relationship between lossof-function mutations in the FLG predisposing to AD and bronchial asthma in association with AD, as well as strong evidence for an association between FLG mutations and other allergic phenotypes that occur in the context of the atopic march (12). These results support the role of filaggrin in the pathogenesis of AD and in the subsequent progression to other allergic diseases that is called the atopic march.…”

Section: Genetics Of Adsupporting

confidence: 56%

Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis

Terada

2009

J Pharmacol Sci

View full text Add to dashboard Cite

Abstract. It has been recognized that atopic dermatitis (AD) involves allergen-driven Th2 cell polarization. In patients with AD, cytokines induce allergic inflammatory responses and subsequently enhance IgE production. Recent reports revealed that a reduced barrier function as well as altered immunity are fundamental to the development of AD because barrier disruption due to aberrant filaggrin expression is a pathological factor. However, although recent studies have improved our understanding of the pathogenesis of AD, the overall pathophysiology remains elusive. I herein discuss it based on the natural history of AD.Keywords: atopic dermatitis, nonatopic dermatitis, barrier dysfunction, filaggrin, IgE autoantibody, allergic inflammation Clinical manifestations of atopic dermatitis (AD)AD is a chronic inflammatory skin disease characterized by itchy dermatitis and susceptibility to cutaneous bacterial, viral, and fungal infections. Other hallmarks of AD are a defect in the barrier function, causing dry skin, and IgE-mediated sensitization to food and environmental allergens (1). The clinical manifestations of AD vary with age. There are three stages: 1) in infancy, the first eczematous lesions usually appear on the cheeks and scalp; 2) in childhood, lesions involve flexures and the extensor aspects of the limbs; and 3) in adolescence and adulthood, lichenified plaques affect the flexures, face, and neck. In each stage, itching worsens the skin lesions and impairs the patient's quality of life.The prevalence of AD has markedly increased during the past three decades. A total of 45% of all cases of early-onset AD begin within the first 6 months of life, 60% begin during the first year, and 85% before 5 years of age. More than 50% of the children affected up to 2 years of age do not show any signs of IgE-sensitization, but they become sensitized during the course of the disease (2). Up to 70% of these children undergo spontaneous remission before adolescence. Immunopathology of AD

show abstract

Section: Genetics Of Adsupporting

confidence: 56%

Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis

Terada

2009

J Pharmacol Sci

View full text Add to dashboard Cite

show abstract

“…Indeed, patients with severe AD display IgE response to so-called auto-allergens 54 . These structures represent an increasing group of proteins to which the immune systems produces IgE auto-antibodies due to their homology with environmental allergens.…”

Section: Evidence For Ige-mediated Autoimmunity In Atopic Dermatitismentioning

confidence: 99%

Atopic Dermatitis

2010

View full text Add to dashboard Cite

“…Fourth, with a few exceptions, these autoantibodies are not considered pathogenic but rather immunological "fingerprints" of pathological processes associated with the development of systemic autoimmunity (18). In recent years, it has become clear that circulating serum autoantibodies that are reactive with intracellular proteins (generically termed antinuclear autoantibodies) are not a unique feature of systemic autoimmune or rheumatic diseases but are also present in a variety of human disease conditions where there is immune system involvement, including but not limited to atopic dermatitis (19,20), chronic fatigue syndrome (21), interstitial cystitis (20), inflammatory diseases of the eye (22,23), and cancer (24 -38).…”

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Casiano

Mediavilla-Varela

Tan

2006

Molecular & Cellular Proteomics

122

106

View full text Add to dashboard Cite

The recognition that human tumors stimulate the production of autoantibodies against autologous cellular proteins called tumor-associated antigens (TAAs) has opened the door to the possibility that autoantibodies could be exploited as serological tools for the early diagnosis and management of cancer. Cancer-associated autoantibodies are often driven by intracellular proteins that are mutated, modified, or aberrantly expressed in tumor cells and hence are regarded as immunological reporters that could help uncover molecular events underlying tumorigenesis. Emerging evidence suggests that each type of cancer might trigger unique autoantibody signatures that reflect the nature of the malignant process in the affected organ. The advent of novel genomic, proteomic, and high throughput approaches has accelerated interest in the serum autoantibody repertoire in human cancers for the discovery of candidate TAAs. The use of individual anti-TAA autoantibodies as diagnostic or prognostic tools has been tempered by their low frequency and heterogeneity in most human cancers. However, TAA arrays comprising several antigens significantly increase this frequency and hold great promise for the early detection of cancer, monitoring cancer progression, guiding individualized therapeutic interventions, and identification of novel therapeutic targets. Our recent studies suggest that the implementation of TAA arrays in screening programs for the diagnosis of prostate cancer and other cancers should be preceded by the optimization of their sensitivity and specificity through the careful selection of the most favorable combinations of TAAs.

show abstract

Autoimmunity and atopic dermatitis

Abstract: Patients suffering from severe manifestations of atopy mount IgE autoantibodies against a variety of human proteins. The levels of IgE autoantibodies correspond with disease severity. Several mechanisms of IgE autoimmunity may contribute to the pathogenesis of atopic dermatitis.

Cited by 76 publications

References 34 publications

Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis

Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Overview of the Pathophysiology of Atopic Dermatitis

Atopic Dermatitis

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Contact Info

Product

Resources

About